Anna Alonso Saladrigues
Investigador pre-doc
Research group
Anna Alonso Saladrigues graduated in Medicine in 2008 at the Universitat Autònoma de Barcelona and she obtained a specialty in Pediatrics and Specific Areas in 2013 at the Universitat de Barcelona. In 2013, she finished the Master's Degree in Pediatric Hematology at the Universitat de Barcelona. She obtained the Postgraduate Master's Degree in "Research Methodology: Design and Statistics in Health Sciences" at the Universitat Autònoma de Barcelona in 2018.
She has focused her professional career in the field of hematology oncology and for the past 6 years she has been an assistant doctor at the Leukemia, Lymphoma and Histiocytosis Unit and a reference doctor at the CAR-T Unit of Hospital Sant Joan de Déu Barcelona since her creation.
Regarding therapeutic advances, she actively participates as a co-investigator in all clinical trials of CAR-T therapy at Hospital San Juan de Dios Barcelona, in clinical trials of hematology oncology, as well as in studies subsidized by official bodies.
Her postgraduate degree in applied statistics in health sciences has enabled her to perform the work of data manager of the unit and collaborate in the statistical analysis of the national database of the SEHOP (Sociedad Española de Hematología y Oncología Pediátrica).
SJD Barcelona Children's Hospital Last Publications
- Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell-Burriel M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives-Solà S and Pérez-Simón JA Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring FRONTIERS IN IMMUNOLOGY . 14: 1280580-1280580.
- Marina Caballero Bellón, Alonso-Saladrigues A, Bobillo-Perez S, Faura A, Arqués L, Rivera C, Català-Temprano A, Dapena JL, Rives-Solà S and Jordán-García I Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study FRONTIERS IN IMMUNOLOGY . 14: 1219289-1219289.
- Ortiz-Maldonado V, Alonso-Saladrigues A, Español-Rego M, Martínez-Cibrián N, Faura A, Magnano L, Català-Temprano A, Benítez-Ribas D, Giné E, Díaz-Beyá M, Correa JG, Rovira M, Montoro-Lorite M, Martínez-Roca A, Rodríguez-Lobato LG, Cabezón R, Cid J, Lozano M, Garcia-Rey E, Conde N, Pedrals G, Rozman M, Torrebadell-Burriel M, Setoain X, Rodríguez S, Esteve J, Pascal M, Urbano-Ispizua Á, Juan-Otero M, Delgado J and Rives-Solà S Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease AMERICAN JOURNAL OF HEMATOLOGY . 97(6): 731-739.
Projects
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Estudio multicéntrico fase 2 en pacientes pediátricos (0-18 años) con leucmeia linfoblástica aguda B CD19+ en recaída o refractaria
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- ICI21/00033
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Análisis de los factores pronósticos de fracaso del tratamiento tras terapia con células T con receptores antigénicos quiméricos (CAR-T) en pacientes pediátricos con leucemia linfoblástica aguda de línea B
- Leader
- Susana Rives Solà, Montserrat Torrebadell Burriel
- Funding entities:
- Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
- Code
- PI21/00218
- Starting - finishing date:
- 2022 - 2024